The Three-Substituted Indolinone Cyclin-Dependent Kinase 2 Inhibitor 3-[1-(3H-Imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) Kills Human Leukemia Cells via Down-Regulation of Mcl-1 through a Transcriptional Mechanism

Mechanisms of lethality of the three-substituted indolinone and putatively selective cyclin-dependent kinase (CDK)2 inhibitor 3-[1-(3H-imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) were examined in human leukemia cells. Exposure of U937 and other leukemia cells to SU9516 concentrations ≥5 μM rapidly (i.e., within 4 h) induced cytochrome c release, Bax mitochondrial translocation, and apoptosis in association with pronounced down-regulation of the antiapoptotic protein Mcl-1. These effects were associated with inhibition of phosphorylation of the carboxyl-terminal domain (CTD) of RNA polymerase (Pol) II on serine 2 but not serine 5. Reverse transcription-polymerase chain reaction analysis revealed pronounced down-regulation of Mcl-1 mRNA levels in SU9516-treated cells. Similar results were obtained in Jurkat and HL-60 leukemia cells. Furthermore, cotreatment with the proteasome inhibitor N-benzoyloxycarbonyl (Z)-Leu-Leu-leucinal (MG132) blocked SU9516-mediated Mcl-1 down-regulation, implicating proteasomal degradation in diminished expression of this protein. Ectopic expression of Mcl-1 largely blocked SU9516-induced cytochrome c release, Bax translocation, and apoptosis, whereas knockdown of Mcl-1 by small interfering RNA potentiated SU9516 lethality, confirming the functional contribution of Mcl-1 down-regulation to SU9516-induced cell death. It is noteworthy that SU9516 treatment resulted in a marked increase in reactive oxygen species production, which was diminished, along with cell death, by the free radical scavenger N-acetylcysteine (NAC). We were surprised to find that NAC blocked SU9516-mediated inhibition of RNA Pol II CTD phosphorylation on serine 2, reductions in Mcl-1 mRNA levels, and Mcl-1 down-regulation. Together, these findings suggest that SU9516 kills leukemic cells through inhibition of RNA Pol II CTD phosphorylation in association with oxidative damage and down-regulation of Mcl-1 at the transcriptional level, culminating in mitochondrial injury and cell death.

[1]  Wei‐Chien Huang,et al.  Transcriptional regulation of cyclooxygenase-2 in response to proteasome inhibitors involves reactive oxygen species-mediated signaling pathway and recruitment of CCAAT/enhancer-binding protein delta and CREB-binding protein. , 2005, Molecular biology of the cell.

[2]  P. Atadja,et al.  Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells , 2005, Molecular Cancer Therapeutics.

[3]  P. Dent,et al.  Apoptosis Induced by the Kinase Inhibitor BAY 43-9006 in Human Leukemia Cells Involves Down-regulation of Mcl-1 through Inhibition of Translation* , 2005, Journal of Biological Chemistry.

[4]  W. Plunkett,et al.  Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. , 2005, Blood.

[5]  Hiroshi Yasui,et al.  Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. , 2005, Blood.

[6]  Xiaodong Wang,et al.  Mule/ARF-BP1, a BH3-Only E3 Ubiquitin Ligase, Catalyzes the Polyubiquitination of Mcl-1 and Regulates Apoptosis , 2005, Cell.

[7]  D. Lane,et al.  Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. , 2005, Cancer research.

[8]  Pierre Dubus,et al.  Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27(Kip1) and p21(Cip1). , 2005, Cancer cell.

[9]  Andrew D Westwell,et al.  Modulation of pRB/E2F functions in the regulation of cell cycle and in cancer. , 2005, Current cancer drug targets.

[10]  P. Hinds,et al.  Cyclins and cdks in development and cancer: a perspective , 2005, Oncogene.

[11]  Y. Xiong,et al.  Biochemical and cellular mechanisms of mammalian CDK inhibitors: a few unresolved issues , 2005, Oncogene.

[12]  D. Cobrinik.  Pocket proteins and cell cycle control , 2005, Oncogene.

[13]  A. Ballestrero,et al.  Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis. , 2005, Blood.

[14]  Michael Karin,et al.  Reactive Oxygen Species Promote TNFα-Induced Death and Sustained JNK Activation by Inhibiting MAP Kinase Phosphatases , 2005, Cell.

[15]  D. Coppola,et al.  Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells , 2005, Cancer biology & therapy.

[16]  S. Korsmeyer,et al.  Obligate Role of Anti-Apoptotic MCL-1 in the Survival of Hematopoietic Stem Cells , 2005, Science.

[17]  T. Kuwana,et al.  BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. , 2005, Molecular cell.

[18]  P. Dent,et al.  Contribution of Disruption of the Nuclear Factor-κB Pathway to Induction of Apoptosis in Human Leukemia Cells by Histone Deacetylase Inhibitors and Flavopiridol , 2004, Molecular Pharmacology.

[19]  S. Grant,et al.  Small molecule inhibitors targeting cyclin-dependent kinases as anticancer agents , 2004, Current oncology reports.

[20]  H. Handa,et al.  A Novel Hydrogen Peroxide-induced Phosphorylation and Ubiquitination Pathway Leading to RNA Polymerase II Proteolysis* , 2004, Journal of Biological Chemistry.

[21]  B. Aronow,et al.  Control of Bcl-2 expression by reactive oxygen species , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[22]  A. Senderowicz.  Small-molecule cyclin-dependent kinase modulators , 2003, Oncogene.

[23]  Pierre Dubus,et al.  Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice , 2003, Nature Genetics.

[24]  J. Cui,et al.  Novel pyrrolyllactone and pyrrolyllactam indolinones as potent cyclin-dependent kinase 2 inhibitors. , 2003, Bioorganic & medicinal chemistry letters.

[25]  Richard A. Woo,et al.  Cyclin-Dependent Kinases and S Phase Control in Mammalian Cells , 2003, Cell cycle.

[26]  Frank McCormick,et al.  Proliferation of cancer cells despite CDK2 inhibition. , 2003, Cancer cell.

[27]  I. Gojo,et al.  The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  Jia-qing Li,et al.  Cyclin A correlates with carcinogenesis and metastasis, and p27(kip1) correlates with lymphatic invasion, in colorectal neoplasms. , 2002, Human pathology.

[29]  S. Wadler,et al.  SU9516, a cyclin-dependent kinase 2 inhibitor, promotes accumulation of high molecular weight E2F complexes in human colon carcinoma cells. , 2002, Biochemical pharmacology.

[30]  Sergei Nekhai,et al.  HIV-1 Tat Interaction with RNA Polymerase II C-terminal Domain (CTD) and a Dynamic Association with CDK2 Induce CTD Phosphorylation and Transcription from HIV-1 Promoter* , 2002, The Journal of Biological Chemistry.

[31]  G. Biamonti,et al.  Cell cycle‐dependent dynamic association of cyclin/Cdk complexes with human DNA replication proteins , 2002, The EMBO journal.

[32]  Li Fang,et al.  Inhibition of p21‐mediated ROS accumulation can rescue p21‐induced senescence , 2002, The EMBO journal.

[33]  Jorge A. Almenara,et al.  The cyclin-dependent kinase inhibitor flavopiridol disrupts sodium butyrate-induced p21WAF1/CIP1 expression and maturation while reciprocally potentiating apoptosis in human leukemia cells. , 2002, Molecular cancer therapeutics.

[34]  G. Mcmahon,et al.  A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells. , 2001, Cancer research.

[35]  M. Mathews,et al.  Three RNA Polymerase II Carboxyl-terminal Domain Kinases Display Distinct Substrate Preferences* , 2001, The Journal of Biological Chemistry.

[36]  R. Tsien,et al.  Inhibition of NF-κB Activation by Arsenite through Reaction with a Critical Cysteine in the Activation Loop of IκB Kinase* , 2000, The Journal of Biological Chemistry.

[37]  R. Young,et al.  Association of Cdk-activating kinase subunits with transcription factor TFIIH , 1995, Nature.

[38]  A. Evens,et al.  Oxidative stress and apoptosis: a new treatment paradigm in cancer. , 2006, Frontiers in bioscience : a journal and virtual library.

[39]  Yihong Ma,et al.  Flavopiridol-induced apoptosis is mediated through up-regulation of E2F1 and repression of Mcl-1. , 2003, Molecular cancer therapeutics.

[40]  R. Jove,et al.  Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis. , 2003, Cancer research.

[41]  R. Tsien,et al.  Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase. , 2000, The Journal of biological chemistry.

[42]  L Meijer,et al.  Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. , 1997, European journal of biochemistry.